Patent classifications
C12N2740/16023
Multivalent particles compositions and methods of use
Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.
MULTIVALENT HIV VACCINE BOOST COMPOSITIONS AND METHODS OF USE
Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521A11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.
USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof.
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
This invention relates to novel anti-HIV antibodies that can be used in the treatment and detection of human immunodeficiency virus (HIV). These antibodies exhibit a high degree of sensitivity and can provide a broad range of specificity.
Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof.
VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIES
The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy.
VESICLES FOR TRACELESS DELIVERY OF GUIDE RNA MOLECULES AND/OR GUIDE RNA MOLECULE/RNA-GUIDED NUCLEASE COMPLEX(ES) AND A PRODUCTION METHOD THEREOF
The present invention describes vesicles carrying gRNA(s) and/or CRISPR-associated RNA guided-nuclease ribonucleoprotein complexes (RNPs) that are efficiently delivered into target cells through fusogenic envelope proteins.
VLP-based bivalent Ebola vaccines and methods of making and using same
Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
VIRUS-LIKE PARTICLES AND USE THEREOF
A virus-like particle encapsulating a target protein is provided. The virus-like particle contain a Gag protein, and the Gag protein forms a dimer with the target protein.
Virus-like particles
Provided herein are membrane enveloped virus-like particles (VLPs), and methods of use and synthesis thereof. In particular, yeast-cell-derived VLPs are provided that comprise surface-displayed glycoproteins and/or multiple virally-derived proteins.